Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
ConditionCancer Patients
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeni-Suef University
About this trial
The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.
Eligibility criteria
Qualifiers
Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.
Disqualifiers
-History of allergic reactions attributed to drugs in the study.
Pregnant women.
Life expectancy less than 6 months
Inability or unwillingness to comply with research protocols.
Trial design
Treatments tested in this trial
- diosmin/hesperdin
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov